Meeting
2021 ASCO Annual Meeting
Capmatinib in MET exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study.
Authors
Juergen Wolf
Department of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany
Juergen Wolf , Edward B. Garon , Harry J.M. Groen , Daniel Shao-Weng Tan , Anna Robeva , Sylvie Le Mouhaer , Mariana Carbini , Andrea Chassot-Agostinho , Rebecca Suk Heist
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02414139
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9020)
DOI
10.1200/JCO.2021.39.15_suppl.9020
Abstract #
9020
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Efficacy and safety of vebreltinib in patients with advanced NSCLC harboring MET exon 14-skipping: Results of 2.5-year follow-up in KUNPENG.
First Author: Jin-Ji Yang
Poster
2021 ASCO Annual Meeting
Capmatinib efficacy in patients with NSCLC identified as METex14 using an NGS-based liquid biopsy assay: Results from the GEOMETRY mono-1 study.
First Author: Rebecca Suk Heist
Poster
2020 ASCO Virtual Scientific Program
Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non–small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study.
First Author: Harry J.M. Groen
Poster
2017 ASCO Annual Meeting
Efficacy of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated anaplastic thyroid cancer (ATC).
First Author: Vivek Subbiah